Pharmaceutical market caps: Daiichi Sankyo down 60% in 2 years as industry rankings shift

Daiichi Sankyo has fallen in the rankings of Japanese pharmaceutical companies by market capitalization, declining approximately 60% over 2 years. Its market capitalization peaked at ¥11.9703 trillion in July 2024 and now stands at ¥5.3707 trillion, placing it 4th behind Takeda Pharmaceutical and Otsuka Holdings.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

The leading Japanese pharmaceutical companies by market capitalization are changing. While Daiichi Sankyo, which has focused on developing oncology drugs, has seen its valuation decline, Takeda Pharmaceutical and Otsuka Holdings have moved up the rankings on investor expectations.

Daiichi Sankyo's market capitalization stood at ¥5.3707 trillion as of the 2nd, down approximately 55% from the record ¥11.9703 trillion reached in July 2024.

It is currently ranked 4th, behind Chugai Pharmaceutical, Takeda and Otsuka Holdings.

At a glance

Market capitalizationDaiichi Sankyo had a market capitalization of ¥5.3707 trillion as of the 2nd

Highest market capitalization¥11.9703 trillion in July 2024, the highest on record

DecreasedDown approximately 55% from the peak

RankCurrently ranked 4th.

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

NikkeiNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.